Quest Diagnostics (DGX) continues to impress with strong results, and notable
yearly returns that have exceeded 20%. The technicals for the stock present a cautious picture, but the fundamentals indicate potential for growth. In fact, the stock posted a record high before ending lower, emphasising its volatile nature. However, the company's
recent acquisition of Allina Health's select lab assets and Fresenius Medical Care's clinical testing assets demonstrates a positive growth trajectory. Recent movements like declaring a
quarterly cash dividend and releasing new testing for the Oropouche Virus show a clear focus on generating shareholder value and expanding their offering. Despite neutral analyst consensus, DGX beat estimates in their Q2 2025 earnings report and raised guidance for the financial year. The company's partnership with
Google Cloud to utilise AI in healthcare data transformation provides an exciting glimpse into the future of patient experience. Collaborations to develop multi-cancer blood tests brings promise, while their launch of an FDA-cleared blood test for Alzheimer's, with a 97% predictive accuracy, is testament to their innovative strategies in the biotech market.
Quest Diagnostics DGX News Analytics from Tue, 03 Dec 2024 08:00:00 GMT to Sat, 23 Aug 2025 13:40:49 GMT -
Rating 8
- Innovation 7
- Information 10
- Rumor -6
